NCODA Logo

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

PTCE and NCODA to Partner in Bringing Oncology-Focused Continuing Education to the NCODA Membership

August 26, 2020

The industry-leading continuing pharmacy education provider becomes sole provider for association’s three major meetings through 2021 (CRANBURY, N.J. – August 23, 2020) – PTCE proudly announces it is now the exclusive continuing education (CE) provider for the National Community Oncology Dispensing Association, Inc. (NCODA) 2020-2021 meetings. See Full Press Release here
read more

FDA granted accelerated approval to tazemetostat for follicular lymphoma

July 7, 2020

On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, […]
read more

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma

June 29, 2020

On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Learn more Product Information Prescribing Information Relapsed or refractory […]
read more

Oncolytics Today Applies For BPA Worldwide Business Publication Membership

June 23, 2020

Shelton, CT June 2020 – Oncolytics Today announced it has applied for business publication membership in BPA Worldwide. Oncolytics Today is published by the National Community Oncology Dispensing Association, Inc. (NCODA) (Cazenovia, NY). BPA Worldwide will analyze Oncolytics Today’s circulation size – including print and digital editions – source make-up, demographics and geographic coverage. The […]
read more

UNM Comprehensive Cancer Center

June 5, 2020

MISSION STATEMENT/PHILOPSOPHY: To ensure that all New Mexicans have access to world-class cancer care and benefit from advances in cancer research, the UNM Comprehensive Cancer Center will provide outstanding cancer diagnosis and treatment, conduct world-class research to discover the causes and the cures for cancer, educate the next generation of cancer healthcare professionals, and overcome […]
read more

St. Elizabeth Healthcare

May 13, 2020

MISSION STATEMENT/PHILOPSOPHY: St. Elizabeth is here for each patient along every step of their journey. We offer a unique approach to patient care that helps us to ensure that all patient needs are met and can be found in one location. LOCATION(S): St. Elizabeth Healthcare is located in Northern Kentucky with locations in Edgewood, Florence, […]
read more

U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma

May 4, 2020

HORSHAM, Pa., May 1, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. DARZALEX FASPRO™ is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as […]
read more

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

April 21, 2020

Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administration. TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or […]
read more

Bristol Myers Squibb (BMS) Expanded Patient Support Program Overview

April 14, 2020

In light of the developing situation around COVID-19, we would like to share immediate action Bristol Myers Squibb is taking to support the health and well-being of patients, customers and employees during this time. Bristol Myers Squibb is expanding its longstanding patient support programs to help eligible unemployed patients in the U.S. who have lost […]
read more

Clearview Cancer Institute

April 10, 2020

MISSION STATEMENT/PHILOPSOPHY: Clearview Cancer Institute is committed to providing cutting edge quality, compassionate, comprehensive care. LOCATION(S): Anniston Location, Athens Location, Cullman Location, Decatur Location, Florence Location, Huntsville-Crestwood Location, Huntsville- Main Location, Jasper Location, Scottsboro Location PRACTICE DETAILS (how many providers, how many employees, etc): Clearview Cancer Institute Consists of 22 Physicians and 20 APP’s QUALIFICATIONS/CREDENTIALS […]
read more

Oncology Consultants

March 24, 2020

MISSION STATEMENT/PHILOPSOPHY: Oncology Consultants mission is a commitment to provide state-of-the-art cancer treatment in a caring environment. LOCATION(S): OC Pharmacy located in the Memorial City Area OC Pharmacy II located in the Medical Center OCRX Pharmacy Solutions located in the Katy Area PRACTICE DETAILS (how many providers, how many employees, etc): Oncology Consultants was formed […]
read more

**IMPORTANT UPDATE** NCODA SPRING FORUM 2020

March 9, 2020

NCODA Spring Forum 2020 Transitions to Virtual E-Meeting March 10, 2020 3pm Eastern To our valued members and corporate partners, In alignment with our Guiding Values, 1) Patient-Centered and 2) Always Collaborative, NCODA is taking all necessary precautions in order to provide our members and corporate partners a value-added experience, while remaining vigilant concerning the […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA Logo

NCODA is a 501(c)(3) Organization